Vaxil Bio Ltd (V:VXL) — Market Cap & Net Worth
Market Cap & Net Worth: Vaxil Bio Ltd (VXL)
Vaxil Bio Ltd (V:VXL) has a market capitalization of $277.45K (CA$383.54K) as of April 20, 2026. Listed on the V stock exchange, this Canada-based company holds position #35110 globally and #1980 in its home market, demonstrating a -6.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vaxil Bio Ltd's stock price CA$0.14 by its total outstanding shares 2739579 (2.74 Million).
Vaxil Bio Ltd Market Cap History: 2015 to 2026
Vaxil Bio Ltd's market capitalization history from 2015 to 2026. Data shows growth from $198.18K to $277.45K (3.26% CAGR).
Vaxil Bio Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vaxil Bio Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of VXL by Market Capitalization
Companies near Vaxil Bio Ltd in the global market cap rankings as of April 20, 2026.
Key companies related to Vaxil Bio Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $111.94 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #298 globally with a market cap of $77.99 Billion USD.
- UCB SA (BR:UCB): Ranked #455 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx SE (SA:A1RG34): Ranked #456 globally with a market cap of $51.73 Billion USD ( R$263.66 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $111.94 Billion | $441.20 |
| #298 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $77.99 Billion | $750.57 |
| #455 | UCB SA | BR:UCB | $51.74 Billion | €263.90 |
| #456 | argenx SE | SA:A1RG34 | $51.73 Billion | R$169.59 |
Vaxil Bio Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Vaxil Bio Ltd's market cap moved from $198.18K to $ 277.45K, with a yearly change of 3.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$277.45K | -3.45% |
| 2025 | CA$287.36K | +1350.00% |
| 2024 | CA$19.82K | -60.00% |
| 2023 | CA$49.54K | +25.00% |
| 2022 | CA$39.64K | -73.33% |
| 2021 | CA$148.63K | -75.00% |
| 2020 | CA$594.53K | +757.14% |
| 2019 | CA$69.36K | +16.67% |
| 2018 | CA$59.45K | -53.85% |
| 2017 | CA$128.82K | -35.00% |
| 2016 | CA$198.18K | 0.00% |
| 2015 | CA$198.18K | -- |
End of Day Market Cap According to Different Sources
On Apr 20th, 2026 the market cap of Vaxil Bio Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $277.45K USD |
| MoneyControl | $277.45K USD |
| MarketWatch | $277.45K USD |
| marketcap.company | $277.45K USD |
| Reuters | $277.45K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vaxil Bio Ltd
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada.